Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Short Interest Down 27.6% in August

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) was the recipient of a significant decline in short interest during the month of August. As of August 31st, there was short interest totalling 13,100 shares, a decline of 27.6% from the August 15th total of 18,100 shares. Approximately 1.0% of the shares of the company are short sold. Based on an average daily trading volume, of 7,300 shares, the days-to-cover ratio is presently 1.8 days.

Creative Medical Technology Stock Down 4.1 %

Shares of CELZ traded down $0.14 during trading hours on Tuesday, reaching $3.25. 11,810 shares of the company traded hands, compared to its average volume of 77,236. The stock has a market capitalization of $4.38 million, a P/E ratio of -0.88 and a beta of 2.11. The business has a fifty day moving average price of $3.42 and a 200-day moving average price of $4.21. Creative Medical Technology has a 12-month low of $2.90 and a 12-month high of $10.28.

Creative Medical Technology (NASDAQ:CELZ) last announced its quarterly earnings data on Friday, August 9th. The company reported ($1.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.27). The firm had revenue of $0.01 million during the quarter. As a group, research analysts predict that Creative Medical Technology will post -3.29 EPS for the current fiscal year.

Hedge Funds Weigh In On Creative Medical Technology

A hedge fund recently bought a new stake in Creative Medical Technology stock. Aaron Wealth Advisors LLC acquired a new stake in Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 16,400 shares of the company’s stock, valued at approximately $85,000. Aaron Wealth Advisors LLC owned about 1.21% of Creative Medical Technology at the end of the most recent reporting period. Institutional investors and hedge funds own 1.42% of the company’s stock.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc, a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease.